caa a22 4500 445338237 CHVBK 20180317142803.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1245/s10434-010-1295-6 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1295-6 Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers [Elektronische Daten] [Yih-Leong Chang, Chen-Tu Wu, Jin-Yuan Shih, Yung-Chie Lee] Background: To obtain insight into the cancer progression and metastatic process, we evaluate p53/epidermal growth factor receptor (EGFR) somatic aberrations in non-small-cell lung cancers to compare accumulated genetic alterations between primary tumors and lymph node metastases. Materials and Methods: A total of 56 primary lung cancers with corresponding lymph node metastases were identified to investigate somatic mutations and altered expressions of p53 and EGFR for clonality assessment. Genomic DNA was extracted from macrodissected cells of paraffin-embedded primary tumor and metastatic lymph node tissues. Overexpression and somatic mutations in exons of p53 (exons 5-8) and tyrosine kinase domain of EGFR (exons 18-21) were examined by immunohistochemical staining and DNA sequencing, respectively. Results: p53 and EGFR mutation/overexpression status were different between primary tumors and lymph node metastases in 5.4/7.2% and 28.6/33.9%, respectively. In most cases, the p53 and EGFR mutations usually preceded lymph node metastasis, and these gene statuses in the primary cancer and their lymph node metastasis were concordant (92.9 and 69.6%, respectively), which further supported the hypothesis that when these p53 mutations occur before the establishment of lymph node metastasis, they subsequently persist in the metastatic nodes. The expressions of p53 and EGFR showed 7.1 and 33.9% discordance in that order. Conclusions: Our results reveal that p53 and EGFR mutations usually precede lymph node metastasis. The higher prevalence of EGFR heterogeneity existing in the primary tumor is not reflected in all lymph node metastasis and thus might have therapeutic implications when adjuvant therapy is considered. Society of Surgical Oncology, 2010 Chang Yih-Leong Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut Wu Chen-Tu Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut Shih Jin-Yuan Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut Lee Yung-Chie Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 543-550 1068-9265 18:2<543 2011 18 10434 https://doi.org/10.1245/s10434-010-1295-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1295-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chang Yih-Leong Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut NATIONALLICENCE 700 1- Wu Chen-Tu Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut NATIONALLICENCE 700 1- Shih Jin-Yuan Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut NATIONALLICENCE 700 1- Lee Yung-Chie Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 543-550 1068-9265 18:2<543 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer